Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -5.64
- Piotroski Score 2.00
- Grade Buy
- Symbol (MTCR)
- Company Metacrine, Inc.
- Price $0.49
- Changes Percentage (0%)
- Change $0.49
- Day Low $0.49
- Day High $0.49
- Year High $0.49
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 06/21/2023
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 08/08/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.03
- Trailing P/E Ratio -0.56446601941748
- Forward P/E Ratio -0.56446601941748
- P/E Growth -0.56446601941748
- Net Income $-61,235,000
